Through Calls for Proposals, we find smart new ideas to help to alleviate the burden of diseases such as HIV/AIDS, tuberculosis and malaria, which often affect the poorest people in society.
Unitaid is pleased to announce this call for proposals aimed at building and refining effective delivery strategies for new vector control tools to catalyze adoption and address emerging threats.
Unitaid is pleased to announce this call for proposals aimed at mitigating antimalarial drug resistance in Africa through interventions that rapidly diversify artemisinin-based combination therapy (ACT) use
Unitaid is pleased to announce a new Call for Proposals on Supporting the use of TRIPS flexibilities and other intellectual property-related solutions to facilitate access to health products.
Unitaid is pleased to announce a new Call for Proposals for the area for intervention: Optimizing the management of coinfections and comorbidities in people living with HIV. Building on prior work to introduce accessible optimal tools for screening and diagnosis, prevention, and treatment of Advanced HIV Disease (AHD) in low- and middle-income countries, Unitaid seeks to further support simplification and decentralization of the AHD care package, including for children.
Unitaid is pleased to announce a new Call for Proposals on Prevention of hepatitis C among key populations.
Unitaid is pleased to announce a new Call for Proposals on the area for intervention: Accelerating tools to drive tuberculosis (TB) detection.
Unitaid is pleased to announce a new Call for Proposals in the Area for Intervention: New tools for reducing maternal mortality.
Under this Call, Unitaid is soliciting proposals aimed at accelerating the adoption and scale-up of IPTi in moderate-to-high transmission settings.
In the context of maternal and child health, Unitaid has identified the opportunity to support the elimination target of congenital transmission of Chagas disease in endemic countries.
For the purpose of this call, Unitaid defines ‘long-acting products’ to mean sustained/extended release products that allow slow absorption of administered drugs maintaining their effects over long periods of time (i.e., over a week for oral products, over a month for injectables and other devices such as implants, patches or rings). The expected change in public health impact for the new products, compared to current daily oral formulations, would need to be explained in each case as it differs depending on disease and indication.
